Key statistics
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.00 |
---|---|
High | 245.55 |
Low | 245.55 |
Bid | -- |
Offer | -- |
Previous close | 245.55 |
Average volume | -- |
---|---|
Shares outstanding | 809.25m |
Free float | 731.58m |
P/E (TTM) | 19.38 |
Market cap | 208.98bn CHF |
EPS (TTM) | 13.23 CHF |
Annual div (ADY) | 9.98 EUR |
---|---|
Annual div yield (ADY) | -- |
Div ex-date | Mar 14 2024 |
Div pay-date | Mar 18 2024 |
Data delayed at least 15 minutes, as of Jun 28 2019 13:06 BST.
More ▼
- Roche’s Vabysmo prefilled syringe (PFS) approved in the EU for three retinal conditions that can cause blindness
- Roche receives CE Mark for new and updated molecular cobas 6800/8800 systems, enhancing laboratory efficiency and testing capabilities
- New and updated data for Roche's fixed-duration Columvi and Lunsumio at ASH 2024 reinforce their potential to improve outcomes for people with lymphoma
- Roche commences tender offer for all shares of Poseida Therapeutics, Inc. for $9.00 per share in cash, plus a non-tradeable contingent value right for up to $4.00 per share in cash
- Five-year results confirm Roche’s Polivy combination therapy as new standard of care for previously untreated aggressive lymphoma
- FDA accepts supplemental Biologics License Application for Roche’s Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma
- Roche enters into a definitive agreement to acquire Poseida Therapeutics, including cell therapy candidates and related platform technologies
- Roche reports update on Phase III SKYSCRAPER-01 study results
- Roche to present new and encouraging long-term follow-up data across broad haematology portfolio at ASH 2024
- Roche presents new data at CTAD, demonstrating its growing momentum in diagnostics for Alzheimer’s disease
More ▼